摘要
目的:探讨帕罗西汀联合左旋多巴对帕金森病患者HAMD评分及QOL评分的影响。方法:选取2015年1月-2019年1月收治的帕金森病患者92例,根据随机数字表法分为研究组和对照组,各46例。对照组给予左旋多巴治疗,研究组给予帕罗西汀联合左旋多巴治疗。比较两组患者治疗后抑郁症状改善情况、疾病改善情况、不良反应发生情况及生活质量情况。结果:治疗前和治疗1周后,两组HAMD评分及UPDES评分比较,差异均无统计学意义(P>0.05);治疗1、2个月后,研究组HAMD评分及UPDRS评分均低于对照组及治疗前,差异均有统计学意义(P<0.05)。治疗2个月后,研究组左旋多巴每日用量少于对照组(P<0.05);研究组不良反应总发生率为10.9%,明显低于对照组的28.3%,差异有统计学意义(P<0.05);治疗2个月后,研究组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论:与单纯采用左旋多巴治疗相比,帕金森患者采用帕罗西汀联合左旋多巴治疗临床效果更佳,患者抑郁症状、神经功能得到有效改善,生活质量有明显提高,且安全性较好,值得推广应用。
Objective:To investigate the effect of Paroxetine combined with Levodopa on HAMD score and QOL score in patients with Parkinson’s disease.Method:A total of 92 patients with Parkinson’s disease admitted from January 2015 to January 2019 were selected.According to the random number table method,they were divided into study group and control group,46 cases in each group.The control group was treated with Levodopa,while the study group was treated with Paroxetine combined with Levodopa.After treatment,the improvement of depression symptoms,disease improvement,adverse events and quality of life of the two groups were compared.Result:Before treatment and 1 week after treatment,the HAMD score and UPDES score between the two groups were compared,the differences were not statistically significant(P>0.05).After 1 and 2 months of treatment,the HAMD score and UPDRS score of the study group were lower than those of before treatment and control group,the differences were statistically significant(P<0.05).After 2 months of treatment,the daily dose of Levodopa in the study group was lower than that in the control group(P<0.05).The overall incidence of adverse reactions in the study group was 10.9%,significantly lower than the 28.3%of the control group,the difference was statistically significant(P<0.05).After 2 months of treatment,the quality of life score of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion:Compared with Levodopa alone,Paroxetine combined with Levodopa has a better clinical effect on patients with Parkinson’s disease.The depression symptoms and neurological functions of the patients have been effectively improved,and the quality of life has been significantly improved.In addition,the safety is better,so it is worthy of promotion and application.
作者
刘琳
李双阳
徐莹
LIU Lin;LI Shuangyang;XU Ying(Shenyang Jishuitan Hospital,Shenyang 110000,China)
出处
《中国医学创新》
CAS
2020年第3期57-60,共4页
Medical Innovation of China
关键词
帕金森病
抑郁症状
左旋多巴
帕罗西汀
生活质量
Parkinson’s disease
Depressive symptoms
Levodopa
Paroxetine
Quality of life
